Annual Secretarial Compliance Report for the financial year ended 31.03.2026.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bal Pharma Ltd has submitted its Annual Secretarial Compliance Report for FY 2025-26, certified by Practising Company Secretary Parameshwar G Bhat. The report identifies three non-compliances: (1) a 43-day delay in constituting the Board of Directors resulting in a Rs 2,15,000 fine from NSE, (2) a 3-day delay in Audit Committee constitution with Rs 6,000 fine, and (3) a 3-day delay in Nomination and Remuneration Committee constitution with Rs 6,000 fine. All penalties have been paid. The company generally maintains good compliance across other areas including secretarial standards, website disclosures, document preservation, performance evaluation, related party transactions, and insider trading regulations. No directors are disqualified and no statutory auditor changes occurred during the year.
The non-compliances relate to minor delays in committee constitutions and carry relatively small fines (totaling Rs 2,27,000). While not severe, these delays indicate governance gaps that investors should monitor. The company has paid all fines and appears to be in substantial compliance overall.